May 25, 2023CorporateTerumo Blood and Cell Technologies Optimizing Cell Therapy Production Through Industry’s First Apheresis Training for Cell Therapy ManufacturersTerumo Blood and Cell Technologies presents data on collection efficiency process with Spectra Optia® Apheresis System at major conferences
May 15, 2023CorporateTerumo to Construct a New Manufacturing Facility at its Kofu Factory for the Medical Care Solutions Company52.2 Billion JPY Capital Investment to Strengthen the Production Capability to Meet the Growing Global Demands
Investors Japanese Financial Results for the Fiscal Year Ended 3/2023 May 15, 2023 IR Library Audio Webcast Stock Quote Prime Market of TSE: Last Trade JPY Change JPY (%) Volume View Chart Top Management Message Shinjiro Sato, President and CEO GS26: 5-Year Growth strategy 2022 - 2026 Terumo Report Sustainability What's New May 17, 2023 Q&A regarding Financial Results for FYE 3/2023 May 16, 2023 Audio webcast regarding Financial Results for FYE 3/2023 May 15, 2023 Presentation regarding Financial Results for FYE 3/2023 February 13, 2023 Q&A regarding Financial Results for the Third Quarter of FYE 3/2023 February 13, 2023 Audio webcast regarding Financial Results for the Third Quarter of FYE 3/2023 View all Business Overview Introduction to the businesses operated by the Terumo Group /business Technology Introduction to Terumo's research and development activities and production system /technology